sellWeak cluster of 510b5-1 plan
Henry E. Pelish sold $3.4M of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 35,104 shares at an average of $98.08, traded Mar 12, 2026, filed Mar 16, 2026.
Warning score
30Value
$3.4M
35,104 shares
Holdings after
65,604
-35% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$3.4M at market
- +10Share of holdings soldSold 35% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0002029477-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | MOption exercise Class A Common Stock10b5-1 | +8,456 | $18.93 | $160k | 91,844 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Class A Common Stock10b5-1 | +1,754 | $27.85 | $49k | 93,598 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Class A Common Stock10b5-1 | +4,125 | $29.33 | $121k | 97,723 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Class A Common Stock10b5-1 | +2,985 | $72.35 | $216k | 100,708 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -24,189 | $97.79 | $2.4M | 76,519 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,505 | $98.44 | $542k | 71,014 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -306 | $99.12 | $30k | 70,708 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -804 | $97.89 | $79k | 69,904 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,597 | $98.83 | $257k | 67,307 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,703 | $99.71 | $170k | 65,604 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,456 | $0.00 | $0 | 2,113 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,754 | $0.00 | $0 | 11,402 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,125 | $0.00 | $0 | 9,900 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,985 | $0.00 | $0 | 21,073 | Mar 16, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.